Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Apalutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Notably, the addition of apalutamide to ADT improved the MFS percentage among the Decipher high-risk patients to a level similar to the percentage among patients classified as Decipher low-to-average-risk.
Brand Name : ARN-509
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2021
Lead Product(s) : Apalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Antibody-drug conjugate
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Apricot Capital
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : The series A financing will help in accelerating Medilink's innovative pipeline development and to support its unique conjugate technology platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 01, 2021
Lead Product(s) : Antibody-drug conjugate
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Apricot Capital
Deal Size : $50.0 million
Deal Type : Series A Financing
Lead Product(s) : Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Japan Approves Dexamethasone as Coronavirus Treatment
Details : The full results of the large randomised clinical trial released in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 22, 2020
Lead Product(s) : Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Limaprost Alfadex
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Nichi-Iko will convert the formulation of “Limaprost Alfadex tablets 5 µg to a formulation which has been improved for moisture resistance stability following the technology transfer.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 05, 2020
Lead Product(s) : Limaprost Alfadex
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Peptide vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Oncogen Researchers Propose Personalized Vaccinomics Strategy for the Novel China Coronavirus
Details : OncoGen researchers propose a novel approach for producing epitope-based peptide vaccine candidates for the novel China coronavirus (nCoV).
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 28, 2020
Lead Product(s) : Peptide vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Berubicin
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : CNS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : For the large scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 14, 2020
Lead Product(s) : Berubicin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : CNS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?